Autism (autism spectrum disorder, ASD) is a disorder of brain development that affects a person’s perception, communication and social skills, usually manifests itself in early childhood, and requires a special approach and support so that children with autism can reach their potential and lead a fulfilling life.
The main features of autism include limited interests and activities, withdrawal in communication and social relationships, repetitive movements or habits, sensitivity to changes and stimuli in the environment, and difficulties in speaking and perceiving information. Children with autism can have different levels of development, ranging from a significant developmental limitation to a high level.
NEW TREATMENT PROTOCOL 2026:Stem Cell Therapy Of Development Delay Diseases – Patient Reviews and Outcomes
Understanding the nature of autism and the development of new treatment methods open ways to improve the lives of children and adults. One of the promising directions is cell therapy, which uses mesenchymal stromal cells (MSCs) to stimulate the development and restoration of brain functions. The story related to a boy named Peleg once again attracted the attention of the world public and became evidence of the effectiveness of this type of therapy.
Orli and the story of her youngest son, Peleg, exemplify the important challenge parents face when they notice changes in their child’s development. In the first two years, Peleg developed normally and began to speak little by little, communicate with others, demonstrating social skills. However, closer to the age of two, Orly noticed changes in his behavior and communication. Loss of eye contact, reduced use of words, and decreased interactivity became obvious signs of change.In addition, Peleg began to lag behind in the development of other skills. He did not know how to play with other children. He became a fan of repetitive movements, slept less and less at night, became extremely picky about food, began to lose weight. The mother faced difficulties in finding an explanation for these changes and finding the right help. She took steps to support her son’s speech development, including speech therapy and physical therapy. Although Orly noticed a small improvement, after a while Peleg lost the acquired skills again, requiring constant efforts to progress and prevent regression.
OUR CLINIC’S STRONG SIDES: Stem Cell Treatment Abroad: An International Clinic with Advanced Regenerative Medicine Solutions
Eventually, after much searching on the Internet, Orly learned about autism. She recognized in Peleg many characteristic symptoms that indicated the presence of an autistic spectrum disorder. This was an important step towards understanding and getting the right care for my son.
Peleg was diagnosed with ASD at the age of 2, but children with autism are still considered “disabled” in Israel. Orly was reimbursed for the costs of the examination and began to receive help to care for her son. Despite the opinions of many parents regarding vaccines and autism, Peleg was not vaccinated on time, so his autism cannot be attributed to this factor.
Orly has undergone genetic testing of the entire family and now knows that a gene linked to autism runs in their family. However, the diagnosis of autism was only the beginning. The mother was still looking for a treatment that could help Peleg. She learned about cell therapy for autism and started talking to other parents who had tried it. Closer to the age of 4, Peleg slept only three hours a night. He lost several kilograms of weight. Orly and her husband Roy decided to try cell therapy anyway. “There is nothing harmful about this therapy – what have I got to lose?” In August 2022, Orly and Roy took Peleg to the clinic. The family spent a week and Peleg received cell therapy for five days.
According to the clinic:
day one – Peleg received an intravenous infusion containing 79 million MSC cells from umbilical cord tissue (UC-MSC).
the second day – he received an infusion of 80 million MSC cells from the placenta (PL-MSC).
on days three and four, he received intramuscular buttock injections of 32 million PL-MSCs and 34 million UC-MSCs, respectively.
Finally, Peleg received two daily intranasal doses of exosomes (EVs) from placental MSCs, which the laboratory certificate describes as a minimum of 400 million EVs with a maximum size of 200 nm.
Registered clinical trials of cell therapy for autism are conducted by infusion of cells through a vein or intrathecal injection into the spinal cord. There are no clinical trials using intramuscular injections of the cells. There has also never been any clinical trial of exosomes for autism.
However, we can compare doses of cells administered intravenously. Peleg received two intravenous infusions with a dose of 4.75 million MSCs per kilogram of body weight (at that time his weight was 16.7 kg).
In comparison, the largest clinical trial of UC-MSCs for children with autism at Duke used a dose of 6 million MSCs/kg, but only one dose. Thus, the net dose of IV MSCs was approximately 50% higher than the dose at Duke, if cell viability was comparable at both centers.
After cell therapy, Peleg quickly began to change. The night after the first infusion, Peleg slept through the night. Orly took many photos and videos of Peleg to document his behavior. Two days after the first infusion, he said his first three words: “Mommy, I’m hungry.” Within a week, he started playing hide and seek with his sister for the first time. Since that time, Peleg has progressed rapidly in many aspects of behavior. The improvements in language skills were too rapid to be explained by standard treatment methods. His speech-language pathologist says that within six months of the cell therapy, he had made progress equivalent to four years.
This is just one case report and does not guarantee results for other children, but Peleg’s family is very glad they took a chance on cell therapy for autism.
Orly and Peleg’s story underscores the need for increased autism awareness, access to screening and treatment for children with ASD. It is important to provide parents with the information and support they need, and to develop scientific research and innovation to improve the quality of life for children with autism.
BE FREE TO CONTACT FOR PERSONAL CONSULTATION:
TEL: +380972524876 ( WHATSAPP)
E-MAIL: info@bioage.com.ua